---
title: "Bambusa Therapeutics climbs 9%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304130016.md"
description: "Bambusa Therapeutics rose 8.88% to US$17.42."
datetime: "2026-11-03T14:32:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304130016.md)
  - [en](https://longbridge.com/en/news/304130016.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304130016.md)
generator: "portal-rs"
---

# Bambusa Therapeutics climbs 9%

Bambusa Therapeutics (BBTX.US) climbed nearly **9%** during regular trading to **$17.42**.

The Nasdaq Composite is down 4.52% over the past five sessions.

Bambusa Therapeutics previously completed an oversubscribed initial public offering priced at $16 per share, raising $169 million and reaching a fully diluted market cap of $856 million.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [BBTX.US](https://longbridge.com/en/quote/BBTX.US.md)

## Related News & Research

- [Bambusa Therapeutics Director Helmut Wolfgang Jeggle Reports $6 Million Common Share Acquisition](https://longbridge.com/en/news/304008064.md)
- [Peter Kolchinsky and Rajeev Shah Disclose 14.6% Stake in Bambusa Therapeutics](https://longbridge.com/en/news/304691682.md)
- [Lenovo Group: Record sales and adjusted profit growth were offset in reported results by warrant revaluation losses](https://longbridge.com/en/news/306059225.md)
- [Is ServiceNow (NOW) Trading At Too High A Premium For Earnings?](https://longbridge.com/en/news/306039339.md)
- [BUZZ-Street View: Nvidia's AI story intact despite uncertainty at top](https://longbridge.com/en/news/305945171.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**